文献速递艾滋病与性传播感染

超深度测序揭示HIV-1感染儿童整合酶抑制剂多药耐药变异选择动态

Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本病例研究对一名快速出现拉替拉韦方案失败的HIV-1感染儿童进行纵向血浆样本分析,采用超深度测序(UDS)检测整合酶基因区耐药变异。结果显示UDS可早于Sanger测序发现少数耐药变异,并揭示E92Q+N155H双突变快速成为优势株及后续Y143R出现导致的多重耐药模式,提示UDS在早期监测耐药动态中的价值。

要点

  • UDS可检测低至1%的少数耐药变异,早于Sanger测序发现N155H。
  • E92Q+N155H双突变导致对整合酶抑制剂全类耐药,包括多替拉韦。
  • 纵向UDS有助于揭示耐药变异的动态演变和连锁关系。

核心结论

  • 本病例研究说明UDS可用于检测早期少数耐药变异并确定纵向分析中HIV-1变异的选择动态。

研究设计与样本

  • 病例研究,对一名HIV-1感染儿童在基线及第4、8、13、17、39周采集纵向血浆样本,并获取母亲基线血浆样本。
  • 对整合酶基因进行Sanger测序和基于Roche 454 GS-Junior的超深度测序(UDS),并开发生物信息学流程识别主要耐药突变、辅助突变及突变连锁。

主要发现

  • 基线和母亲样本中Sanger测序和UDS均未检测到整合酶基因少数耐药变异。
  • 第4周UDS检测到N155H占4%序列,Sanger测序未检测到。
  • 第8周出现E92Q+N155H双突变(16%),第13周快速成为优势株(57%)。
  • 第17周(拉替拉韦最后时间点)出现Y143R,耐药突变模式包括单突变N155H(47%)和Y143R(24%),双突变E92Q+N155H(13%)、Y143R+N155H(2%)和E92Q+Y143R(2%)。
  • 多态性替换M50I优先在耐药变异上被选择,尤其在E92Q+N155H变异上。

临床怎么用

  • 对于HIV-1感染儿童快速失败于拉替拉韦方案者,可考虑UDS早期检测少数耐药变异以指导治疗调整。
  • UDS纵向监测有助于识别对整合酶抑制剂全类耐药的突变模式(如E92Q+N155H),避免后续药物选择受限。

局限性

  • 本研究为单病例报告,结果外推需谨慎。
  • UDS阈值设为1%,可能漏检低于1%的变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ultra-deep sequencing (UDS) allows detection of minority resistant variants (MRVs) with a threshold of 1% and could be useful to identify variants harbouring single or multiple drug-resistance mutations (DRMs). OBJECTIVES: We analysed the integrase gene region longitudinally using UDS in an HIV-1-infected child rapidly failing a raltegravir-based regimen. METHODS: Longitudinal plasma samples at baseline and weeks 4, 8, 13, 17 and 39 were obtained, as well as the mother's baseline plasma sample. Sanger sequencing and UDS were performed on the integrase gene using Roche 454 GS-Junior. A bioinformatic workflow was developed to identify the major DRMs, accessory mutations and the linkage between mutations. RESULTS: In Sanger sequencing and UDS, no MRV in the integrase gene was detected at baseline in either the mother or the child. The major DRM N155H conferring resistance to raltegravir and elvitegravir was detected in 4% of the sequences by week 4 using UDS, whereas it was not detected by Sanger sequencing. The double mutant E92Q + N155H, conferring resistance to the entire integrase inhibitor class, including dolutegravir, emerged at week 8 (16%) and became rapidly dominant (57% by week 13). At the last timepoint under raltegravir (week 17), Y143R emerged, leading to different resistance mutation patterns: single mutants N155H (47%) and Y143R (24%) and double mutants E92Q + N155H (13%), Y143R + N155H (2%) and E92Q + Y143R (2%). The polymorphic substitution M50I was preferentially selected on resistant variants, especially on E92Q + N155H variants. CONCLUSIONS: This case study illustrates the usefulness of UDS in detecting early MRVs and determining the dynamics of selected HIV-1 variants in longitudinal analysis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Stefic K, Salmona M, Capitao M, et al. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing. J Antimicrob Chemother. 2017. PMID: 27999055. doi:10.1093/jac/dkw507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。